GSK has partnered with Relation Therapeutics in a deal potentially worth $110 million to advance AI-driven drug discovery. The collaboration will focus on generating large-scale datasets that measure human cell responses to genetic changes and drug interventions. These datasets will be used to train AI models, including Relation's MORGAN platform, to identify potential drug targets. The partnership builds on previous work between the companies and highlights the critical role of high-quality biological data in developing effective AI models for drug discovery. AI
IMPACT This collaboration underscores the growing importance of high-quality biological data in training effective AI models for drug discovery, potentially accelerating the identification of new therapeutic targets.
RANK_REASON Partnership between a major pharmaceutical company and a biotech firm focused on AI drug discovery. [lever_c_demoted from significant: ic=1 ai=0.7]
Read on Artificial Intelligence News →
- Experimental and Molecular Medicine
- GSK
- Human Cell Atlas
- Lab-in-the-Loop
- MORGAN
- Nature Methods
- NCBI Gene Expression Omnibus
- Relation Therapeutics
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
